Ontology highlight
ABSTRACT: Importance
Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions.Objective
To assess the efficacy and safety of the topical phosphodiesterase 4 inhibitor PF-07038124 in patients with AD and plaque psoriasis.Design, setting, and participants
This phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across 4 countries. Eligible patients (aged 18-70 years) had mild to moderate AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area). Data were analyzed until December 15, 2021.Interventions
Patients were randomized (1:1) to PF-07038124, 0.01%, topical oin
SUBMITTER: Eichenfield LF
PROVIDER: S-EPMC10733847 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature